The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
This activity is eligible for AMA PRA Category 1 Credits™; see the final activity announcement for details.
ABIM MOC Points
This activity is eligible for ABIM MOC Points; see the final activity announcement for details.
After participating in CROI 2020, participants will be able to:
- Describe current basic science research on the pathogenesis of HIV and on advances toward a cure
- List the most recent findings from clinical trials in the field of HIV and the implications of these data for state-of-the-art treatment strategies
- Describe current epidemiologic data on the prevalence of HIV infection, transmission, treatment, and linkage to and retention in care in populations worldwide; the implications of these data for public-health program planning; and current advances in biobehavioral prevention
Statement of Need
Since HIV was identified, the scientific response to the global pandemic has been a coordinated effort among basic researchers, clinical investigators, health care providers, epidemiologists, and community leaders to move information and potential treatment options from research to clinical trials and out to affected communities as quickly as possible. CROI was founded in 1993 by researchers working in the field of HIV/AIDS and its complications, as a science-focused forum for exchanging current research findings among their international peers. CROI continues to focus on scientific exchange, providing an environment in which basic science researchers, translational researchers, clinical investigators, epidemiologists, and public health experts meet to present and discuss the latest research into different facets of HIV and its complications, as well as selected other emerging infections.
Disclosure of Financial Relationships
It is the policy of the IAS–USA to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty members (planners, speakers, presenters, etc) participating in IAS–USA-sponsored activities are required to disclose to the program audience any financial relationships with commercial interests within the past 12 months that could be perceived to influence, or give the appearance of potentially influencing, the written or oral presentation. The Accreditation Council for Continuing Medical Education (ACCME) defines a financial interest as an interest in any amount and defines a commercial interest as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.” The information is intended to make the IAS–USA audience aware of speaker and contributor interests and commitments with commercial interests, enabling the audience members to form their own judgments about such associations.
Each author or contributor is required to complete this financial disclosure declaration. In accordance with IAS–USA policy, the IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Financial relationship information about faculty members is included with the Program and Abstracts eBook on the web.
Drug and Product Disclamer
This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.
The Conference on Retroviruses and Opportunistic Infections (CROI) is largely supported by the registration fees of participants. In addition, in the interest of objective, balanced, and scientifically rigorous activities, the IAS–USA seeks grant support from commercial companies, particularly from companies with competing products. These companies have no input in or control over the selection of faculty or content of the presentations.
The 2020 Conference on Retroviruses and Opportunistic Infections has, to date, received grant support commitments from the following commercial companies:
Gilead Sciences, Inc.
Merck & Co., Inc.